This Article explores a proposal that would preclude biased drug testing by removing all drug sponsor influence on the design and conduct of clinical trials for new drug applications (“NDAs”), a reform that would address the root of institutional corruption. Recently advocated by leading scholars, the idea has a long history, yet was neglected for over half a century due to pharmaceutical industry opposition.
Marc A. Rodwin,
Independent Drug Testing to Ensure Drug Safety and Efficacy,
18 J. Health Care L. & Pol'y
Available at: http://digitalcommons.law.umaryland.edu/jhclp/vol18/iss1/3